Jaguar Health, a San Francisco-based pharmaceutical company with 49 employees, specializes in plant-derived medicines for gastrointestinal issues in humans and animals, including Mytesi for HIV patients and Canalevia-CA1 for dogs. The company went public on May 13, 2015, and operates through human and animal health segments.
Jaguar Health (JAGX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Jaguar Health's actual EPS was -$16.70, beating the estimate of -$18.36 per share, resulting in a 9.04% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
